CHICAGO, June 4, 2011 /PRNewswire/ — Genomic Health, Inc.
(Nasdaq:
GHDX) today announced results of ten studies being presented at
the American Society of Clinical Oncology (ASCO) Annual Meeting,
including a second large validation study confirming the
performance of the Oncotype DX® colon cancer Recurrence
Score® (RS) as an independent predictor of recurrence risk in
stage II colon cancer. The company also will present positive
findings from a prostate gene identification study, as well as
multiple studies in breast cancer including one suggesting that
neoadjuvant treatment selection can also be guided by the
underlying biology revealed by the Oncotype DX breast cancer
test.
“Our continued research in breast, colon and prostate cancers
add to the growing body of clinical evidence demonstrating the
importance of understanding and treating a patient’s underlying
individual tumor biology,” said Steven Shak, M.D., chief medical
officer at Genomic Health, “These ten studies presented at
ASCO reflect our ability to continue adding value to the
Oncotype DX breast and colon cancer tests that physicians
use today, while accelerating our prostate cancer clinical
development program, with the goal of making a test for biopsy
specimens available to patients and physicians in 2013.”
Research Highlights:
Colon Cancer:
Second Successful Prospectively-Designed Study Confirms
Oncotype DX Colon Cancer Test Provides Value Beyond
Conventional Markers
Supporting the original QUASAR study presented at ASCO in 2009,
new results from a separate large clinical validation study of
stage II colon cancer patients enrolled in CALGB 9581 further
confirms that the Oncotype DX Recurrence Score result
improves the ability to differentiate higher from low
‘/>”/>
SOURCE